To address this, we first assessed cell cytotoxicity by SRB assay in control (NT) and DYRK1A-KO colon (HCT-116) and TNBC (SUM159, MDA-MB-231) cancer cells using 2 different chemotherapy drugs that target cells in the G1/S phase, topotecan and cisplatin31,32. Here, DYRK1A is linked to cancer.